Mumbai, Feb. 14 -- The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of Upjohn US 2 LLC.

Latanoprost ophthalmic solution is used to treat certain types of glaucoma and other causes of high pressure inside the eye.

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution market had achieved annual sales of approximately $113.5 million.

Marc Kikuchi, president & business head, North America, said: "We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel."

Glenmark Pharmaceutic...